PubMed:23257958 JSONTXT

{"project":"PubMed_Structured_Abstracts","denotations":[{"id":"T1","span":{"begin":151,"end":675},"obj":"OBJECTIVE"},{"id":"T2","span":{"begin":685,"end":935},"obj":"METHODS"},{"id":"T3","span":{"begin":945,"end":1347},"obj":"RESULTS"},{"id":"T4","span":{"begin":1360,"end":1463},"obj":"CONCLUSIONS"}],"text":"Placenta-derived mesenchymal stem cells have an immunomodulatory effect that can control acute graft-versus-host disease in mice.\nBACKGROUND AND AIMS: Immunomodulatory properties of mesenchymal stem cells (MSCs) have been applied to reduce the incidence of graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). Among the various sources of MSCs that have immunomodulatory effects in vitro, only placenta-derived MSCs (PD-MSCs) have not been evaluated in an in vivo model of GVHD. In this study, we investigated the immunomodulatory properties of PD-MSCs in vitro and evaluated their clinical potential for controlling GVHD in an animal model.\nMETHODS: A GVHD animal model was established by transplanting C57BL/6 donor bone marrow cells and spleen cells into lethally irradiated BALB/c recipient mice. To control GVHD, human PD-MSCs were transplanted into recipient mice (5 × 10(5) or 1 × 10(6) cells).\nRESULTS: PD-MSCs suppressed mitogen-stimulated T cell proliferation in vitro in a dose-dependent manner. Moreover, PD-MSCs inhibited cytokine secretion (interleukin-12, tumor necrosis factor-α and interferon-γ) of activated T cells. In vivo, the survival rate in the PD-MSC group (transplanted with 1 × 10(6) cells) was higher than that in the control group and histological scores were low in the PD-MSC group.\nCONCLUSION: We present the first evidence that human PD-MSCs can efficiently control GVHD in an HSCT in vivo model."}

{"project":"Allie","denotations":[{"id":"SS1_23257958_2_0","span":{"begin":182,"end":204},"obj":"expanded"},{"id":"SS2_23257958_2_0","span":{"begin":206,"end":210},"obj":"abbr"},{"id":"SS1_23257958_2_1","span":{"begin":257,"end":282},"obj":"expanded"},{"id":"SS2_23257958_2_1","span":{"begin":284,"end":288},"obj":"abbr"},{"id":"SS1_23257958_2_2","span":{"begin":296,"end":335},"obj":"expanded"},{"id":"SS2_23257958_2_2","span":{"begin":337,"end":341},"obj":"abbr"},{"id":"SS1_23257958_3_0","span":{"begin":428,"end":449},"obj":"expanded"},{"id":"SS2_23257958_3_0","span":{"begin":451,"end":458},"obj":"abbr"}],"relations":[{"id":"AE1_23257958_2_0","pred":"abbreviatedTo","subj":"SS1_23257958_2_0","obj":"SS2_23257958_2_0"},{"id":"AE1_23257958_2_1","pred":"abbreviatedTo","subj":"SS1_23257958_2_1","obj":"SS2_23257958_2_1"},{"id":"AE1_23257958_2_2","pred":"abbreviatedTo","subj":"SS1_23257958_2_2","obj":"SS2_23257958_2_2"},{"id":"AE1_23257958_3_0","pred":"abbreviatedTo","subj":"SS1_23257958_3_0","obj":"SS2_23257958_3_0"}],"text":"Placenta-derived mesenchymal stem cells have an immunomodulatory effect that can control acute graft-versus-host disease in mice.\nBACKGROUND AND AIMS: Immunomodulatory properties of mesenchymal stem cells (MSCs) have been applied to reduce the incidence of graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). Among the various sources of MSCs that have immunomodulatory effects in vitro, only placenta-derived MSCs (PD-MSCs) have not been evaluated in an in vivo model of GVHD. In this study, we investigated the immunomodulatory properties of PD-MSCs in vitro and evaluated their clinical potential for controlling GVHD in an animal model.\nMETHODS: A GVHD animal model was established by transplanting C57BL/6 donor bone marrow cells and spleen cells into lethally irradiated BALB/c recipient mice. To control GVHD, human PD-MSCs were transplanted into recipient mice (5 × 10(5) or 1 × 10(6) cells).\nRESULTS: PD-MSCs suppressed mitogen-stimulated T cell proliferation in vitro in a dose-dependent manner. Moreover, PD-MSCs inhibited cytokine secretion (interleukin-12, tumor necrosis factor-α and interferon-γ) of activated T cells. In vivo, the survival rate in the PD-MSC group (transplanted with 1 × 10(6) cells) was higher than that in the control group and histological scores were low in the PD-MSC group.\nCONCLUSION: We present the first evidence that human PD-MSCs can efficiently control GVHD in an HSCT in vivo model."}